any thoughts on which trial will be more difficult to pass? also which one offers the best market opportunity?
from memory lucentis more effective drug
Ann: Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens, page-15
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $371.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 34.0¢ | $279.5K | 814.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 419069 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 86292 | 2 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |